Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Articles and Publications
Case Studies
Charge Capture and Pricing
Coding Integrity
Craneware Insights Articles
News & Events
Press Releases
Trade Shows
Upcoming Events
Value Cycle
White Papers

Grant of Options – Replacement

This replaces the ‘Grant of Options’ announcement released on 13 September 2016 at 14:48 under RNS No 7265J. The number of options granted was corrected to 36,469.

All other details remain unchanged.

The full amended version is shown below.

Craneware plc
(“Craneware”, “the Group” or the “Company”)
Grant of Options
7 October 2016 – The Board of Craneware plc (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, announces that on 12 September 2016, the Remuneration Committee approved the granting of share options to certain Directors to subscribe for ordinary shares of 1p each in the Company as follows:

Director No. of options granted Percentage of issued share capital
Keith Neilson (CEO) 36,469 0.14

The above options have been granted at an exercise price of 1177.5p per share (being the closing market price on 12 September 2016). These options will be subject to performance criteria, such that they vest in three equal tranches over three years. One third of the share options will vest on or after 30 June 2017, one third on or after 30 June 2018 and the final third on or after 30 June 2019. The share options will not become exercisable until three years from the date of the grant.

PDMR notification – Keith Neilson

1.     Details of the Restricted Person / person closely associated with him or her 
a)    Name Keith Neilson
2.     Reason for the notification
a)    Position/status CEO
b)    Initial notification / Amendment Initial notification
3.     Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)    Name Craneware plc
b)    LEI 213800O2CTJ1YFXNXG05
4.     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)    Description of the financial instrument, type of instrument Ordinary shares of 1p each in the capital of Craneware plc
b)    Identification code ISIN GB00B2425G68
c)     Nature of the transaction Grant of options
d)    Price(s) and volume(s) Volume(s) granted 36,469, Price(s) n/a
e)    Aggregated information:
i.  Aggregated volume Aggregate volume granted 36,469
ii. price Price(s) n/a
f)     Date of the transaction 2016-09-12
g)    Place of the transaction London Stock Exchange, (XLON); AIM

For further information, please contact:

Craneware plc

Peel Hunt

  • +44 (0)20 7418 8900
  • Dan Webster
  • Adrian Trimmings
  • George Sellar


  • +44 (0)208 004 4218
  • Caroline Forde
  • Hilary Buchanan
  • Robyn McConnachie

About Craneware

Craneware enables healthcare providers to improve margins and enhance patient outcomes so they can continue to provide quality outcomes for all.

Craneware is the leader in automated value cycle solutions that help US provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Boston and Phoenix employing over 200 staff. Craneware’s market-driven, SaaS solutions normalise disparate data sets, bringing in up-to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit and

Skip to toolbar